Abstract
Objective: To investigate the effects of moxifloxacin on the cornea of normal human eyes using confocal microscopy and slit-lamp biomicroscopy. Methods: This study enrolled adult volunteers who had a normal baseline ophthalmic examination. The dose regimen, similar to that of patients undergoing cataract extraction, was one drop of moxifloxacin in one eye four times a day for 3 days. The untreated fellow eye served as the control. Subjects had a baseline examination (Visit 1), started moxifloxacin the next day, and were examined 24 h (Visit 2) and 72 h (visit 3) after starting medication. At each visit, visual acuity and adverse effects were recorded, slit-lamp examination with fluorescein was used to measure tear break-up time, and endothelial and epithelial cell counts were determined using confocal microscopy. Results: Fifteen volunteers (mean age 37 ± 7 years) enrolled. No significant difference In visual acuity, tear break-up time, endothelial or epithelial cell counts was noted between the treated and fellow eye. Subjects experienced no significant decrease in visual acuity, tear break-up time, or endothelial cell counts during the 3-day treatment period in either eye. Epithelial cell counts were stable at Visits 1 and 2, and decreased similarly in the treated and control eye at Visit 3. Conclusions: Moxifloxacin was safe for use during the 3-day treatment period. Moxifloxacin causes no significant epithelial or endothelial toxicity, and has no effect on visual acuity or ocular surface integrity in healthy subjects treated using a dosing regimen that simulated prophylactic use following cataract surgery.
| Original language | English |
|---|---|
| Pages (from-to) | 2073-2078 |
| Number of pages | 6 |
| Journal | Current Medical Research and Opinion |
| Volume | 22 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 1 2006 |
Fingerprint
Keywords
- Confocal microscopy
- Cornea
- Moxifloxacin
- Toxicity
ASJC Scopus subject areas
- Medicine(all)
Cite this
The effect of moxifloxacin on the normal human cornea. / Donaldson, Kendall; Marangon, Fabiana B.; Schatz, Lauren; Venkatraman, Anna S.; Alfonso, Eduardo C.
In: Current Medical Research and Opinion, Vol. 22, No. 10, 01.10.2006, p. 2073-2078.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The effect of moxifloxacin on the normal human cornea
AU - Donaldson, Kendall
AU - Marangon, Fabiana B.
AU - Schatz, Lauren
AU - Venkatraman, Anna S.
AU - Alfonso, Eduardo C
PY - 2006/10/1
Y1 - 2006/10/1
N2 - Objective: To investigate the effects of moxifloxacin on the cornea of normal human eyes using confocal microscopy and slit-lamp biomicroscopy. Methods: This study enrolled adult volunteers who had a normal baseline ophthalmic examination. The dose regimen, similar to that of patients undergoing cataract extraction, was one drop of moxifloxacin in one eye four times a day for 3 days. The untreated fellow eye served as the control. Subjects had a baseline examination (Visit 1), started moxifloxacin the next day, and were examined 24 h (Visit 2) and 72 h (visit 3) after starting medication. At each visit, visual acuity and adverse effects were recorded, slit-lamp examination with fluorescein was used to measure tear break-up time, and endothelial and epithelial cell counts were determined using confocal microscopy. Results: Fifteen volunteers (mean age 37 ± 7 years) enrolled. No significant difference In visual acuity, tear break-up time, endothelial or epithelial cell counts was noted between the treated and fellow eye. Subjects experienced no significant decrease in visual acuity, tear break-up time, or endothelial cell counts during the 3-day treatment period in either eye. Epithelial cell counts were stable at Visits 1 and 2, and decreased similarly in the treated and control eye at Visit 3. Conclusions: Moxifloxacin was safe for use during the 3-day treatment period. Moxifloxacin causes no significant epithelial or endothelial toxicity, and has no effect on visual acuity or ocular surface integrity in healthy subjects treated using a dosing regimen that simulated prophylactic use following cataract surgery.
AB - Objective: To investigate the effects of moxifloxacin on the cornea of normal human eyes using confocal microscopy and slit-lamp biomicroscopy. Methods: This study enrolled adult volunteers who had a normal baseline ophthalmic examination. The dose regimen, similar to that of patients undergoing cataract extraction, was one drop of moxifloxacin in one eye four times a day for 3 days. The untreated fellow eye served as the control. Subjects had a baseline examination (Visit 1), started moxifloxacin the next day, and were examined 24 h (Visit 2) and 72 h (visit 3) after starting medication. At each visit, visual acuity and adverse effects were recorded, slit-lamp examination with fluorescein was used to measure tear break-up time, and endothelial and epithelial cell counts were determined using confocal microscopy. Results: Fifteen volunteers (mean age 37 ± 7 years) enrolled. No significant difference In visual acuity, tear break-up time, endothelial or epithelial cell counts was noted between the treated and fellow eye. Subjects experienced no significant decrease in visual acuity, tear break-up time, or endothelial cell counts during the 3-day treatment period in either eye. Epithelial cell counts were stable at Visits 1 and 2, and decreased similarly in the treated and control eye at Visit 3. Conclusions: Moxifloxacin was safe for use during the 3-day treatment period. Moxifloxacin causes no significant epithelial or endothelial toxicity, and has no effect on visual acuity or ocular surface integrity in healthy subjects treated using a dosing regimen that simulated prophylactic use following cataract surgery.
KW - Confocal microscopy
KW - Cornea
KW - Moxifloxacin
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=33750503796&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750503796&partnerID=8YFLogxK
U2 - 10.1185/030079906X132668
DO - 10.1185/030079906X132668
M3 - Article
C2 - 17022866
AN - SCOPUS:33750503796
VL - 22
SP - 2073
EP - 2078
JO - Current Medical Research and Opinion
JF - Current Medical Research and Opinion
SN - 0300-7995
IS - 10
ER -